+44 (0)20 8154 4600
info@achillestx.com
Home
About Us
Management Team
Scientific Advisory Board
Board of Directors
Science
Publications
Pipeline
Pipeline
Expanded Access
Investors & Media
Press Releases
Events & Presentations
Quarterly Results
SEC Filings
Governance
Analyst Coverage
ACHL Stock
Tax Information
IR Resources
Careers
Contact
Home
About Us
Management Team
Scientific Advisory Board
Board of Directors
Science
Publications
Pipeline
Pipeline
Expanded Access
Investors & Media
Press Releases
Events & Presentations
Quarterly Results
SEC Filings
Governance
Analyst Coverage
ACHL Stock
Tax Information
IR Resources
Careers
Contact
ACHILLES
MEDIA COVERAGE
BioWorld – Achilles’ I-O approach draws $120M in series B
04th September 2019
READ MORE +
Financial Times – UK biotech secures £100m funding for lung cancer trials
03rd September 2019
READ MORE +
Endpoints – RA Capital-backed cell therapy player in the neoantigen game grabs a $121M megaround to fund first human studies
03rd September 2019
READ MORE +
Scrip – Interview: Achilles Advances Armed With £100m
03rd September 2019
READ MORE +
BioCentury – Achilles Adds £100m To Move Neoantigen T Cell Therapy Into The Clinic
03rd September 2019
READ MORE +
Wall Street Journal Pro Venture Capital – Achilles Therapeutics Eyes T-Cell Therapy for Solid Cancers With New Funding
03rd September 2019
READ MORE +
BioCentury – Achilles’ Truncal Neoantigens
21st January 2019
READ MORE +